Adjustment of guidance for 2025/26

Core Viewpoint - ChemoMetec has adjusted its revenue and EBITDA guidance for the financial year 2025/26 due to several market challenges, despite a strong competitive position in cell counting automation [1][2]. Group 1: Market Challenges - The North American market for cell and gene therapy has been impacted by government lockdowns and geopolitical uncertainties, leading to prolonged decision-making processes among customers [5]. - The implementation of automation in the production of cell and gene therapies has proven to be more time-consuming than anticipated, causing delays in validations and decisions [5]. - Increased interest in the XcytoMatic platform has resulted in a slowdown in sales of NC instruments and associated consumables [5]. Group 2: Financial Adjustments - Revenue is now expected to be in the range of DKK 490-520 million, a decrease from the previously announced DKK 565-580 million [2]. - EBITDA is projected to be between DKK 260-285 million, down from the earlier guidance of DKK 320-335 million [2]. Group 3: Competitive Position - ChemoMetec continues to see a growing number of automation projects and confirms that its XcytoMatic products remain attractive and competitive in the market [1]. - The upcoming introduction of the new software platform XM Octopus is expected to further strengthen ChemoMetec's market position [1].